Last reviewed · How we verify

Neozepam (NITRAZEPAM)

discontinued Small molecule

Neozepam works by enhancing the activity of the neurotransmitter GABA, which helps to calm down overactive brain activity.

Neozepam, also known as nitrazepam, is a small molecule drug that targets the GABA-A receptor alpha-1/beta-2/gamma-2 subunits. It is a member of the benzodiazepine class and is used to treat insomnia and myoclonic seizures. The commercial status of Neozepam is unclear, and it is not FDA-approved. Neozepam has a half-life of 26 hours and a bioavailability of 78%. It is a potent anxiolytic and anticonvulsant agent.

At a glance

Generic nameNITRAZEPAM
Drug classnitrazepam
TargetGABA-A receptor alpha-1/beta-2/gamma-2
ModalitySmall molecule
Therapeutic areaNeuroscience
Phasediscontinued

Mechanism of action

Imagine your brain is like a busy city with lots of people talking and moving around. GABA is like a traffic cop that helps to slow down the traffic and keep everything calm. Neozepam helps the traffic cop to do its job more effectively, which can help to reduce anxiety and seizures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: